Salud financiera de hoja de balance de Evotec

Salud financiera controles de criterios 4/6

Evotec tiene un patrimonio de los accionistas total de €968.5M y una deuda total de €470.1M, lo que sitúa su ratio deuda-patrimonio en 48.5%. Sus activos y pasivos totales son €2.0B y €1.0B respectivamente.

Información clave

48.5%

Ratio deuda-patrimonio

€470.05m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	€303.27m
Patrimonio	€968.47m
Total pasivo	€1.02b
Activos totales	€1.99b

Actualizaciones recientes sobre salud financiera

Recent updates

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 10

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb

Nov 05

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 17

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 08

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Aug 03

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Apr 10

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Mar 05

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Jan 09

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Oct 05

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Jun 28

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

May 14

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Feb 25

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Jul 29

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (€698.1M) de EVT superan a sus pasivos a corto plazo (€333.6M).

Pasivo a largo plazo: Los activos a corto plazo de EVT (€698.1M) superan a sus pasivos a largo plazo (€688.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (17.2%) de EVT se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de EVT ha pasado de 68.8% a 48.5% en los últimos 5 años.

Cobertura de la deuda: El flujo de caja operativo de EVT es negativo, por lo que la deuda no está bien cubierta.

Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de EVT sobre su deuda están bien cubiertos por el EBIT.

Salud financiera de hoja de balance de Evotec

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Evotec SE announced delayed 20-F filing

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Recent updates

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisitionn of Evotec SE (XTRA:EVT).

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Consensus EPS estimates fall by 54%

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) made a non-binding expression of interest to acquire Evotec SE (XTRA:EVT) for €2 billion.

Triton Reportedly Weighs Takeover Deal for Drug Developer Evotec

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Monacum Partners GmbH acquired Evotec Drug Substance (Germany) GmbH from Evotec SE (XTRA:EVT).

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb

Price target decreased by 22% to €10.65

Consensus EPS estimates fall by 13%

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Price target decreased by 11% to €13.64

Consensus EPS estimates fall by 69%

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 77%

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Price target decreased by 7.0% to €19.26

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Price target decreased by 7.5% to €23.00

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Price target decreased by 7.6% to €23.67

Price target decreased by 8.3% to €24.88

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Price target decreased by 9.1% to €27.14

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Evotec SE, Annual General Meeting, Jun 20, 2023

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

Price target decreased by 8.1% to €24.93

Price target decreased by 9.8% to €24.73

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Price target decreased to €26.72

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Price target decreased to €30.94

Consensus forecasts updated

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Price target decreased to €32.50

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Consensus forecasts updated

Consensus EPS estimates have been upgraded.

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE Revises Revenue Guidance for the Full Year 2022

Consensus forecasts updated

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Now 20% undervalued